2/16/2010

Biotech firm Rigel Pharmaceuticals agreed to license fostamatinib disodium, its rheumatoid arthritis drug, to AstraZeneca in a deal worth as much as $445 million. The experimental treatment finished midstage development and will advance to Phase III study in the second half of this year.

Related Summaries